
Sign up to save your podcasts
Or


Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.
Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.
From the publisher's feed

2 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners

1 Listeners

1 Listeners

0 Listeners

0 Listeners

0 Listeners